Lyrica News and Research

RSS
TheraQuest launches new analgesic product pipeline

TheraQuest launches new analgesic product pipeline

Amended class action complaint against Pfizer

Amended class action complaint against Pfizer

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Tel Aviv University researcher maps drug target to wipe pain away

Tel Aviv University researcher maps drug target to wipe pain away

Pfizer's Neurontin to earn 50% patient share in treatment of postherpetic neuralgia: Survey

Pfizer's Neurontin to earn 50% patient share in treatment of postherpetic neuralgia: Survey

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer's new pipeline shows growth and diversity in research and development

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

FDA issues Pfizer a Complete Response letter for Lyrica GAD monotherapy treatment

FDA issues Pfizer a Complete Response letter for Lyrica GAD monotherapy treatment

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Positive results from Winston Laboratories' Civamide Patch trial

Positive results from Winston Laboratories' Civamide Patch trial

Pfizer announces fiscal 2009 third-quarter results

Pfizer announces fiscal 2009 third-quarter results

PHARMACIA & UPJOHN COMPANY to pay the largest criminal fine ever imposed in the U.S.

PHARMACIA & UPJOHN COMPANY to pay the largest criminal fine ever imposed in the U.S.

Pfizer to continue its Aricept agreement with Eisai

Pfizer to continue its Aricept agreement with Eisai

Lawsuit charged against Pfizer for illegal marketing of Geodon

Lawsuit charged against Pfizer for illegal marketing of Geodon

Pfizer finalizes settlement agreement with U.S. DOJ regarding past promotional practices

Pfizer finalizes settlement agreement with U.S. DOJ regarding past promotional practices

Pfizer to pay $301 million as setlement for illegal off-label promotion of Geodon

Pfizer to pay $301 million as setlement for illegal off-label promotion of Geodon

Pfizer to pay $2.3 billion for health care fraud settlement

Pfizer to pay $2.3 billion for health care fraud settlement

Vulvodynia, the most frequent cause of painful sex

Vulvodynia, the most frequent cause of painful sex

Innexus Biotechnology announces business development initiative on lead preclinical candidate

Innexus Biotechnology announces business development initiative on lead preclinical candidate